R&D Q4 Clinical trials round-up: October to December 2025 We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.
R&D Big promises, hard work: What 2026 will demand from pharma Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.
R&D Clinical research demands agile CROs An emerging consensus across sponsors, investigators, and regulators is that agility must become a defining attribute of CRO performance.
R&D Europe has the tools to fight superbugs. Let’s use them. Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help.
R&D FDA’s emerging framework to reduce animal testing: Implicati... Exploring the strategic shift toward reducing reliance on non-human primates (NHPs) and other animal species in R&D.
R&D Bringing therapies to patients quicker with integrated CDMO ... Biotechs and pharmaceutical companies can receive enormous value from a trusted partnership with an integrated CDMO and CRO.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
